The first human trials of an Ebola vaccine developed using the same technology as the AstraZeneca Covid jab has been started by a team of researchers at the University of Oxford.
The first human trials of an Ebola vaccine developed using the same technology as the AstraZeneca Covid jab has been started by a team of researchers at the University of Oxford. The trial will be conducted on 26 volunteers, aged between 18 and 55 years, to determine the safety and immunogenicity of the vaccine called ChAdOx1 biEBOV.
‘Ebola is a severe, often fatal illness that is transmitted to people from wild animals and then spreads in the human population through direct contact with the blood, secretions, organs or other bodily fluids of infected people.’
It will assess the vaccine's efficacy and the immune response it creates against Zaire and Sudan Ebola virus species in healthy adult volunteers. "We are carrying out a clinical trial of a new Ebola vaccine called 'ChAdOx1 biEBOV' which is designed to target two of the deadliest species of Ebola-causing viruses," according to a statement of the Jenner Institute, University of Oxford.
The vaccine is based on the ChAdOx1 vaccine technology that was previously successfully used to develop the Oxford/AstraZeneca Covid-19 vaccine.
It is developed using adenovirus -- a weakened version of the common cold virus that is genetically modified so that it cannot replicate in humans.
The trial participants will be monitored over a six-month period, with results expected in the second quarter of 2022.
Advertisement
While rVSV-ZEBOV vaccine is currently approved against Ebola, the research team believes "the world needs new vaccines against Ebola".
Advertisement
"We have designed our new vaccine to target the two species of virus that have caused nearly all Ebolavirus outbreaks and deaths, and now look forward to testing this in phase one clinical trials," he added.
The Democratic Republic of Congo is currently seeing an outbreak with eight cases, including six deaths reported since the beginning of October.
Source-IANS